PhoenixBio Co., Ltd. (JP:6190)
:6190
Want to see JP:6190 full AI Analyst Report?
Top Page
PhoenixBio Co., Ltd.
(6190)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥393.00
▼(-18.80% Downside)
Action:Reiterated
Date:05/18/26
The score is driven by a mixed fundamental picture: a meaningful profitability rebound and improving leverage are positive, but multi-year volatility and still-uneven cash flow quality reduce confidence. Valuation looks attractive on a low P/E, while technical signals remain soft with the stock trading below key longer-term moving averages.
Positive Factors
High gross margin & profitability rebound
A sustained gross margin near 76% and a return to positive net income indicate structural pricing power and favorable cost economics for its specialized animal models. High gross margins support durable profit potential, enabling reinvestment in service capabilities and insulating core margins from moderate revenue swings.
Negative Factors
Inconsistent cash generation history
Repeated years of negative operating and free cash flow show the company’s cash profile is cyclical and unpredictable. This weakens confidence that recent positive cash flow will persist, increases reliance on external funding during downturns, and complicates long-term planning for capital and R&D spending.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin & profitability rebound
A sustained gross margin near 76% and a return to positive net income indicate structural pricing power and favorable cost economics for its specialized animal models. High gross margins support durable profit potential, enabling reinvestment in service capabilities and insulating core margins from moderate revenue swings.
Read all positive factors
PhoenixBio Co., Ltd. (6190) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.53B
Dividend YieldN/A
Average Volume (3M)360.67K
Price to Earnings (P/E)12.2
Beta (1Y)0.54
Revenue Growth1.57%
EPS GrowthN/A
CountryJP
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-112.33
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.14
P/FCF Ratio31.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PhoenixBio Co., Ltd. Business Overview & Revenue Model
Company Description
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featu...
How the Company Makes Money
PhoenixBio makes money primarily by selling and servicing preclinical research inputs used in drug discovery and life-science research. Key revenue streams include: (1) sales/supply of experimental animals (including specialized disease model anim...
PhoenixBio Co., Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
66
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49B | 1.57B | 1.54B | 1.72B | 2.12B | 1.32B |
| Gross Profit | 1.09B | 1.19B | 1.11B | 1.20B | 1.56B | 727.79M |
| EBITDA | -245.63M | 116.52M | -396.12M | 87.94M | 537.42M | -305.81M |
| Net Income | -448.70M | 125.23M | -445.65M | 26.38M | 493.33M | -387.97M |
Balance Sheet | ||||||
| Total Assets | 2.23B | 2.19B | 2.31B | 2.74B | 3.02B | 2.28B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 1.15B | 1.15B | 1.39B | 1.56B | 1.33B |
| Total Debt | 503.59M | 486.64M | 565.36M | 723.93M | 1.13B | 1.04B |
| Total Liabilities | 860.05M | 640.05M | 944.82M | 946.58M | 1.50B | 1.45B |
| Stockholders Equity | 1.37B | 1.55B | 1.37B | 1.80B | 1.51B | 828.15M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 56.42M | -94.24M | -118.08M | 265.12M | 9.63M |
| Operating Cash Flow | 0.00 | 68.86M | -73.00M | -79.31M | 277.49M | 16.40M |
| Investing Cash Flow | 0.00 | -13.75M | -27.98M | 115.36M | -156.34M | -6.97M |
| Financing Cash Flow | 0.00 | -88.01M | -128.00M | -244.88M | 86.63M | -34.66M |
PhoenixBio Co., Ltd. Technical Analysis
Negative
484.00
Price Trends
439.62
Negative
455.76
Negative
462.00
Negative
Market Momentum
-15.52
Positive
27.27
Positive
18.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6190, the sentiment is Negative. The current price of 484 is above the 20-day moving average (MA) of 424.85, above the 50-day MA of 439.62, and above the 200-day MA of 462.00, indicating a bearish trend. The MACD of -15.52 indicates Positive momentum. The RSI at 27.27 is Positive, neither overbought nor oversold. The STOCH value of 18.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6190.
PhoenixBio Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | ¥1.53B | 12.22 | ― | ― | 1.57% | ― | |
54 Neutral | ¥137.64B | -14.34 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.88B | -33.05 | ― | ― | -11.11% | -187.80% | |
43 Neutral | ¥3.74B | -47.85 | ― | ― | 1.30% | 92.91% | |
42 Neutral | ¥11.98B | -20.18 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.77B | -8.72 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:6190
PhoenixBio Co., Ltd.
376.00
-6.00
-1.57%
JP:2342
Trans Genic Inc.
222.00
70.00
46.05%
JP:4974
Takara Bio Inc.
1,143.00
356.00
45.24%
JP:4978
ReproCELL Inc.
126.00
-60.00
-32.26%
JP:7774
Japan Tissue Engineering Co., Ltd.
588.00
-10.00
-1.67%
JP:7776
CellSeed Inc.
224.00
-292.00
-56.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.